First-In-Human Study of STX-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations

Recruiting

Phase 1

Phase 2

STX-721First-In-Human Study of STX-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations

Sponsor:

Antares Therapeutics, Inc

Code:

NCT06043817

Conditions

Non-Small Cell Lung Cancer

NSCLC

EGFR/HER2 Exon 20 Insertion Mutation

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

STX-721 (Escalated)

STX-721 (3 dose levels)

STX-721 (RP2D)

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-29. This information was provided to ClinicalTrials.gov by Antares Therapeutics, Inc on 2025-08-06.